Foley Hoag Represents ORIG3N in Funding Round

Foley Hoag LLP represented ORIG3N, Inc., a leader in regenerative medicine and provider of pluripotent stem cell storage, in its recent round of financing in the amount of $3.1 million. Funding came from an investor syndicate that included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

Based in Boston, ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. The funding will support the creation of the world's largest bank of pluripotent stem cells to better understand rare genetic inherited diseases and neurodegenerative diseases such as Parkinson's, Alzheimer's, MS and ALS and develop improved treatments.

The Foley Hoag team representing ORIG3N consisted of attorneys Jeffrey Quillen, Colin Zick, Michael Robbat and Patrick Connolly.